Cary Street Partners’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$158K Sell
301
-6
-2% -$3.37K ﹤0.01% 962
2026
Q1
$173K Buy
307
+7
+2% +$4.49K ﹤0.01% 855
2025
Q4
$203K Buy
300
+5
+2% +$3.4K 0.01% 833
2025
Q3
$188K Sell
295
-10
-3% -$6.07K ﹤0.01% 803
2025
Q2
$164K Buy
+305
New +$146K ﹤0.01% 809

Other funds holding IDXX

Cary Street Partners's IDXX Position: Q2 2026 in Review

Cary Street Partners reduced its Idexx Laboratories (IDXX) stake by 2% in Q2 2026, selling an estimated $3.37K and leaving 301 shares worth $158K. The position accounts for ﹤0.01% of the portfolio, ranked #962.

Cary Street Partners first reported a position in IDXX in Q2 2025 and has held it in 5 quarters since. The position peaked at $203K in Q4 2025. 1,296 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Cary Street Partners held 301 shares of Idexx Laboratories worth $158K as of Q2 2026.
  • Cary Street Partners sold 6 Idexx Laboratories shares in Q2 2026, an estimated $3.37K.
  • Idexx Laboratories made up ﹤0.01% of Cary Street Partners's portfolio in Q2 2026, its #962 holding.
  • Cary Street Partners first reported a position in Idexx Laboratories in Q2 2025 and has held it in 5 quarters since.
  • Cary Street Partners's Idexx Laboratories position peaked at $203K in Q4 2025.
  • 1,296 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Cary Street Partners's 13F filing for Q2 2026, filed 17 Jul 2026.